Altimmune (ALT) Invested Capital (2012 - 2026)

Altimmune's (ALT) quarterly Invested Capital came in at $35.0 million in Q1 2026, little changed on a QoQ basis from $35.0 million in Q4 2025.

Altimmune (ALT) Invested Capital (2012 - 2026) Analysis & Trends

Altimmune (ALT) has 8 years of Invested Capital data on file, last reported at $35.0 million in Q1 2026.

On a quarterly basis, Invested Capital changed N/A year-over-year to $35.0 million in Q1 2026; TTM through Mar 2026 was $100.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $35.0 million, changed N/A from the prior year.
Invested Capital for Q1 2026 stood at $35.0 million, roughly flat from $35.0 million in the prior quarter.
Over the last five years, Invested Capital for ALT reached as high as $35.0 million in Q4 2025 and fell as low as $4.3 million in Q1 2022.
Historically, Invested Capital has averaged $20.9 million across 3 years, with a median of $15.0 million in 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	110.96 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	116.14 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Altimmune	7.96 Mn	7.96 Mn	-	35.00 Mn

Download Data